309 related articles for article (PubMed ID: 14674118)
1. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
2. p53 protein expression in putative precursor lesions of epithelial ovarian cancer.
Hutson R; Ramsdale J; Wells M
Histopathology; 1995 Oct; 27(4):367-71. PubMed ID: 8847068
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
5. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G
J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232
[TBL] [Abstract][Full Text] [Related]
6. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
9. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
10. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
11. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
12. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
13. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
15. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.
Eccles DM; Brett L; Lessells A; Gruber L; Lane D; Steel CM; Leonard RC
Br J Cancer; 1992 Jan; 65(1):40-4. PubMed ID: 1310251
[TBL] [Abstract][Full Text] [Related]
18. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
19. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.
Harlozińska A; Bar JK; Sedlaczek P; Gerber J
Am J Clin Pathol; 1996 Mar; 105(3):334-40. PubMed ID: 8602615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
